Figure 6.
Figure 6. Kinase inhibitor studies and Western blot analysis of kinase pathways in HUVECs exposed to HOSCN. (A) Monolayers of HUVECs were pretreated 1 hour with U0126 (10 μM) or wortmannin (10 nM and 100 nM) and then exposed to buffer or 150 μM HOSCN in M199 medium containing 10% FBS and fresh inhibitors for 4 hours. Western blots of whole cell lysates were probed for phospho-p44/42 (Erk1/2), p44/42 (Erk1/2), phospho-AKT, AKT, and TF. (B) HUVECs were pretreated with 10 μM U0126, 10 μg/mL andrographolide, or wortmannin (10 nM and 100 nM) for 1 hour and then exposed to 150 μM HOSCN in M199 medium containing 10% FBS and fresh inhibitors for 4 hours. TF activity in lysates was determined by one-stage clotting assay. All data are shown ± SD.

Kinase inhibitor studies and Western blot analysis of kinase pathways in HUVECs exposed to HOSCN. (A) Monolayers of HUVECs were pretreated 1 hour with U0126 (10 μM) or wortmannin (10 nM and 100 nM) and then exposed to buffer or 150 μM HOSCN in M199 medium containing 10% FBS and fresh inhibitors for 4 hours. Western blots of whole cell lysates were probed for phospho-p44/42 (Erk1/2), p44/42 (Erk1/2), phospho-AKT, AKT, and TF. (B) HUVECs were pretreated with 10 μM U0126, 10 μg/mL andrographolide, or wortmannin (10 nM and 100 nM) for 1 hour and then exposed to 150 μM HOSCN in M199 medium containing 10% FBS and fresh inhibitors for 4 hours. TF activity in lysates was determined by one-stage clotting assay. All data are shown ± SD.

Close Modal

or Create an Account

Close Modal
Close Modal